Clinical trials: Lipid Disorders
Obesity
A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program
The purpose of this study is to compare the efficacy and safety of topiramate 96mg and 192mg daily) with placebo in the treatment of obesity following an intensive non-pharmacologic weight loss program.
- Trial name
- NCT00236600
- Testing
- topiramate
- Volunteers
- 561 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Fabry Disease
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the alpha-galactosidase A enzyme.
- Trial name
- NCT00196716
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 4 sites in Czechia, Estonia and 2 more
- Volunteers
- 21 people
- Sponsor
- Genzyme, a Sanofi Company
Familial Hypercholesterolemia
Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
This was a long term follow on study to assess the continued long term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia.
- Trial name
- NCT00943306
- Testing
- lomitapide
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 19 people
- Sponsor
- Aegerion Pharmaceuticals, Inc.
GM2 Gangliosidosis, Niemann-Pick Type C Disease
A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
This open-label study aims to gather long-term safety, tolerability, PK, biomarker, and clinical efficacy data relating to daily administration of Nizubaglustat in participants previously enrolled in the Phase 2 RAINBOW study…
- Trial name
- PRISMA (NCT07399704)
- Testing
- AZ-3102
- Where
- 3 sites in Brazil
- Volunteers
- 21 people
- Sponsor
- Azafaros B.V.
Hypercholesterolemia, Coronary Heart Disease
Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis
The purpose of the study is to evaluate the safety and efficacy of dosing with mipomersen for 26 weeks in treating severely hypercholesterolemic patients who are on a maximally tolerated lipid-lowering regimen and who are not on…
- Trial name
- NCT00794664
- Testing
- Mipomersen
- Where
- 27 sites in United States, Canada and 4 more
- Volunteers
- 58 people
- Sponsor
- Kastle Therapeutics, LLC
Vascular Diseases, Hypercholesterolemia
The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus
Double-blind, randomised, placebo-controlled, parallel group study with two intervention arms. The study will be conducted in 150 subjects and the primary objective is to show a fasting LDL-cholesterol and triglyceride lowering…
- Conditions
- Vascular Diseases, Hypercholesterolemia, Diabetes Mellitus
- Trial name
- NCT02288585
- Testing
- Plant sterols
- Where
- 2 sites in Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Lipid Metabolism Disorder
Lipid Management in Clinical Practice (MK-0524A-115)
The aim of this observational program is to generate data on the use of Tredaptive (nicotinic acid/laropiprant) for lipid management under routine medical practice conditions.
- Trial name
- NCT01071278
- Volunteers
- 2,390 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study to Assess Any Potential Interaction Between Colesevelam and Ciclosporin in Healthy Volunteers
This study is designed to assess any potential interaction between colesevelam and ciclosporin in healthy volunteers.
- Trial name
- NCT00692250
- Testing
- Colesevelam hydrochloride film-coated tablets (Cholestagel)
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Hypertension, Hypercholesterolemia
Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and Hypercholesterolemia
This study is to confirm the long-term efficacy and safety of Rosuampin Tab. in patients with hypertension and hypercholesterolemia
- Trial name
- NCT06293261
- Testing
- Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg
- Where
- 39 sites in South Korea
- Volunteers
- 5,047 people
- Sponsor
- Yuhan Corporation
Body Fat Disorder
Non-Invasive Reduction of Fat in the Inner Thighs
Evaluate the safety and efficacy of non-invasive fat reduction in the inner thighs with the ZELTIQ CoolSculpting System.
- Trial name
- NCT01517659
- Testing
- The Zeltiq CoolSculpting System
- Where
- 3 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Acne
Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects
The aim of the study is to understand the structural and functional modifications of the host, the microorganisms, and their interactions (host/microorganism relationship) before and after the RV3278A - ET0943 product application
- Trial name
- NCT05640388
- Testing
- RV3278A - ET0943 cosmetic product, RV4632A - RY1845 cosmetic product
- Where
- 2 sites in France
- Volunteers
- 41 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Type I Hypersensitivity
Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00133159
- Testing
- Grass MATAMPL
- Where
- 3 sites in Canada
- Volunteers
- 68 people
- Sponsor
- Allergy Therapeutics
Hyperlipidemias
Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers
To investigate the pharmacokinetic properties and safety after administration of HCP1105 and co-administration of HGP0918, HGP0816 in healthy male volunteers
- Trial name
- NCT02941796
- Testing
- HCP1105, HCP0918, HCP0816
- Where
- South Korea
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Dyslipidemia
Study to Evaluate the Safety and the Pharmacokinetics of "UI111" and "UIC202006" Under Fed Conditions
Phase 1 study to evaluate the safety and the pharmacokinetics of "UI111" and "UIC202006" in healthy adult volunteers under fed state conditions Open-label, randomized, single-dose, 2-sequence, 4-period, crossover design
- Trial name
- NCT07691268
- Testing
- Administration of UI111, Administration of UIC202006
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Korea United Pharm. Inc.
Obesity, Overweight
The Use of Irvingia Gabonensis (Bush Mango)and Cissus Quadrangularis to Reduce Weight and Blood Lipids
Hypothesis: Cissus quadrangularis as well as Irvingia gabonensis are used in weight management and related conditions. This study set out to investigate if a combination of the two could have additional benefits to overweight and…
- Conditions
- Obesity, Overweight, Dyslipidemia
- Trial name
- NCT00526682
- Testing
- Irvingia/cissus combo
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Gateway Health Alliance
Lipodystrophy, Deformities
Performance and Safety of the Lipo-transfer Cannulas in Patients Underlying Lipofilling Treatment
The purpose of this post-market clinical follow up study is to assess the safety and performance of Aesthetic Group cannulas. The study will evaluate the outcome of the Aesthetic Group cannulas range over a period of 1 month…
- Trial name
- NCT06089759
- Where
- 3 sites in France
- Volunteers
- 108 people
- Sponsor
- Aesthetic Group
Hypercholesterolemia
Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003
To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)
- Trial name
- NCT03847974
- Testing
- LIB003
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- LIB Therapeutics LLC
Hypercholesterolemia
Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)
Evaluate the proportion of hyperlipaemic persons with known coronary heart disease achieving ldl-c goal as defined by the national cholesterol education program (NCEP) adult treatment panel (ATP) III guidelines
- Trial name
- NCT00442897
- Testing
- simvastatin (+) ezetimibe, Comparator: atorvastatin
- Volunteers
- 229 people
- Sponsor
- Organon and Co
Fed
Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition
The purpose of this study is to compare the single oral dose bioequivalence of olanzapine 5 mg OD tablets with Zyprexa Zydis 5 mg tablets under fed conditions and to monitor adverse events and ensure safety of subjects.
- Trial name
- NCT01503450
- Testing
- Olanzapine OD Tablets 5 mg
- Where
- India
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Hyperlipidemia
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneously once every 2 weeks (Q2W) and once monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein…
- Trial name
- RUTHERFORD-2 (NCT01763918)
- Testing
- Evolocumab
- Where
- 39 sites in United States, Australia and 12 more
- Volunteers
- 331 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.